Rentschler Biopharma Kicks off Expansion at U.S. Facility in the Boston Biotech Hub

New 500 L bioreactor in operation mid-2020 at U.S. site

Rentschler Biopharma, is a leading contract development and manufacturing organization (CDMO), focused exclusively on client projects

Rentschler Biopharma SE, a world-class contract development and manufacturing organization (CDMO) for biopharmaceuticals, is taking the first step in the expansion project to grow its U.S. footprint and establish a Center of Excellence in North America, putting into operation a single-use bioreactor for the 93,000 square foot facility in Milford, MA, in the Greater Boston area. The XDR-500 bioreactor, with a working volume of 100-500 L and down stream process capabilities of 2-8 g/L, is part of the state-of-the-art GMP facility suite concept. The system is planned to be client-ready in mid-2020 and is currently being prepared for technology transfer. With its innovative and highly flexible business model, the Milford site is already taking on new projects, including complex and difficult-to-manufacture proteins, e.g. multispecific antibodies.

Further expansion planning includes another building for large-scale manufacturing, which will also be single-use bioreactor manufacturing as well as lab capacity for new modalities. Both, in Europe and the U.S., Rentschler Biopharma will be able to leverage its client-centric approach and expertise in advanced technologies to facilitate the robust and scalable production of complex biomolecules. Dr. Jesús Zurdo, Senior Vice President Innovation and Venture Partnerships, will bring to BIO-Europe Rentschler Biopharma’s knowledge and dedication to science as a foundation to convert medical research into outstanding biopharmaceuticals. In the workshop “Smart Drug Discovery”, Dr. Zurdo, together with other experienced executives, will discuss the implementation of the best business models and technological innovations to follow the most efficient path in new drug development, including innovative manufacturing solutions.